Inflammatory fibroblasts make rectal cancer resistant to radiation therapy
- PMID: 35120597
- DOI: 10.1016/j.ccell.2022.01.005
Inflammatory fibroblasts make rectal cancer resistant to radiation therapy
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. Still, the molecular mechanisms that drive CRC therapy resistance are incompletely understood. In this issue of Cancer Cell, Nicolas et al. combine several approaches to unravel a critical role for inflammatory cancer-associated fibroblasts (iCAFs) and interleukin 1α (IL1α) signaling in radiotherapy resistance.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests F.M-G. received research support from Innate-Pharma, Roche and Bristol-Myers-Squibb (BMS). R.M. declares no potential conflict of interest.
Comment on
-
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer.Cancer Cell. 2022 Feb 14;40(2):168-184.e13. doi: 10.1016/j.ccell.2022.01.004. Epub 2022 Feb 3. Cancer Cell. 2022. PMID: 35120600
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
